Medical devices are different to pharmaceuticals in the Health Technology Assessment process

2014 ◽  
Vol 3 (3) ◽  
pp. 217-219 ◽  
Author(s):  
Michael Ferguson
Keyword(s):  
Health Technology Assessment ◽  
Medical Devices ◽  
Technology Assessment ◽  
Health Technology ◽  
Assessment Process ◽  
Health Technology Assessment Process

scholarly journals ASSESSING THE IMPACTS OF CITIZEN DELIBERATIONS ON THE HEALTH TECHNOLOGY PROCESS – ERRATUM

2013 ◽  
Vol 29 (4) ◽  
pp. 466-466
Author(s):  
J. Abelson ◽  
Y. Bombard ◽  
F. Gauvin ◽  
D. Simeonov ◽  
S. Boesveld
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Assessment Process ◽  
Original Publication ◽  
Technology Process ◽  
Health Technology Assessment Process

In the original publication of ‘Assessing the Impacts of Citizen Deliberations on the Health Technology Process’ the title was published incorrectly. The correct title should be: Assessing the Impacts of Citizen Deliberations on the Health Technology Assessment Process. The publisher regrets this error.

OP484 Analysis Of Horizon Scanning Outputs For The National Institute for Health and Care Excellence Health Technology Assessment Process

2020 ◽  
Vol 36 (S1) ◽  
pp. 10-11
Author(s):  
Sarah Khalid Khan ◽  
Sonia Garcia Gonzalez Moral ◽  
Dapo Ogunbayo ◽  
Dawn Craig
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Influencing Factor ◽  
Health Technology ◽  
Assessment Process ◽  
The European Union ◽  
Time Duration ◽  
Horizon Scanning ◽  
Time Period ◽  
Health Technology Assessment Process

IntroductionThe National Institute for Health Research (NIHR) Innovation Observatory (NIHRIO) is the national Horizon Scanning (HS) organization in England, and the National Institute for Health and Care Excellence (NICE) is its key health technology assessment (HTA) stakeholder. NIHRIO has a remit to notify NICE of innovative technologies with a time horizon of three years prior to regulatory approval in the European Union (EU)/United Kingdom (UK). The notification process produces an initial ‘filtration form’ followed by a ‘technology briefing’ produced 17–20 months prior to licence for those technologies that NICE will consider for appraisal. Since April 2017, NIHRIO has produced ~400 technology briefings. We present an analysis of how this has fed into the NICE HTA process so far.MethodsThe analysis mapped NIHRIO's technology briefings (April 2017 – June 2020) with relevant NICE technology appraisal/highly specialized technologies (TA/HST) guidance during the time period. The analysis followed the timeline of technologies from identification during the horizon scanning process to filtration to briefing submission to NICE and entering the TA/HST process to outcome/recommendation given by NICE.ResultsUntil June 2020, 496 technology briefings entered the NICE TA/HST scoping process. Forty per cent are in progress, four per cent have had a TA/HST recommendation and three per cent that entered the NICE TA/HST scoping process did not complete it. On average it took less time from briefing submission to NICE recommendation for cancer indications. The time from discovery to NICE recommendation ranged from 115 months to 22 months.ConclusionsHS for TA/HST is a lengthy process from identification to final recommendation and there is considerable variation in time duration from identification to briefing submission to NICE recommendation. Average time taken from briefing submission to NICE recommendation is shorter for cancer indications and repurposed medicines. A full TA/HST may not be recommended for all technology briefings, rather they may update existing guidance or find different routes of evaluation. Technologies that enter the TA/HST scoping process might be terminated, suspended or discontinued for several reasons which may include lack of company engagement, change in development or regulatory plans by the company. Timely notification is key in achieving TA/HST recommendation at the time of market authorization but not the only influencing factor.

Health technology assessment process of a cardiovascular medical device in four different settings

2017 ◽  
Vol 6 (7) ◽  
pp. 591-600
Author(s):  
Antonio Olry de Labry Lima ◽  
Jaime Espín Balbino ◽  
Alexandre Lemgruber ◽  
Araceli Caro Martínez ◽  
Leticia García-Mochón ◽  
...  
Keyword(s):  
Health Technology Assessment ◽  
Medical Device ◽  
Technology Assessment ◽  
Health Technology ◽  
Assessment Process ◽  
Health Technology Assessment Process

VP30 Research And Analysis Of European Health Technology Assessment Processes

2017 ◽  
Vol 33 (S1) ◽  
pp. 161-161
Author(s):  
Julia Sus ◽  
Zoe Garrett
Keyword(s):  
Decision Making ◽  
Health Technology Assessment ◽  
Medical Devices ◽  
Technology Assessment ◽  
Health Technology ◽  
General Information ◽  
Assessment Process ◽  
Joint Production ◽  
Member States ◽  
Horizon Scanning

INTRODUCTION:As part of the European Network for Health Technology Assessment (EUnetHTA) Joint Action 3, the National Institute for Health and Care Excellence (NICE) in collaboration with forty-nine Health Technology Assessment (HTA) agencies and payer organizations, is leading on research to gain a high level understanding of HTA processes across Europe. This will help to facilitate improved collaboration and use of EUnetHTA HTA reports and tools across member states and decrease the duplication of work.To analyze the similarities and differences in HTA processes and decision making on the reimbursement of pharmaceuticals and medical devices across Europe.METHODS:National agencies involved in the HTA and reimbursement processes shared data on HTA and decision-making processes. Data provided was extracted into an excel workbook including information relating to pharmaceuticals, medical devices, inpatient and outpatient care and assessments that inform reimbursement, pricing and other processes.RESULTS:Thirty-one countries provided fifty-eight sets of HTA process and procedural documents for both medical devices and pharmaceuticals. This information was translated into the workbook which consisted of eleven sections (general information, capacity, overview of the process, topic selection, assessment process, advice and decision making, legal and procedural issues, reassessment, stakeholders engagement, HTA information used and HTA information held).The first stage of data analysis is a descriptive write up of existing processes from horizon scanning and topic selection up to decision making. The second stage is an analysis showing how collaboration and use of EUnetHTA outputs can be implemented into existing processes. An additional questionnaire will be developed to gain further understanding of EUnetHTA partners views on national engagement in the EUnetHTA procedures, implications of joint production, what EUnetHTA products are most valued and what mechanism might support better information sharing and more efficient use of HTA reports between jurisdictions.CONCLUSIONS:The analysis of the above data will provide detailed information on how EUnetHTA products or HTA products from other jurisdictions could be introduced into HTA and reimbursement processes across member states and at what point could EUnetHTA partners best engage in joint and cooperative work.

The WellPoint Outcomes Based FormularySM: enhancing the health technology assessment process

2005 ◽  
Vol 8 (1-4) ◽  
pp. 13-25 ◽  
Author(s):  
Brian Sweet ◽  
Celynda G Tadlock ◽  
William Waugh ◽  
Andrea Hess ◽  
Ann Nguyen
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Assessment Process ◽  
Health Technology Assessment Process
Sign in / Sign up

Export Citation Format

Share Document